DelveInsight’s “Malignant Pleural Effusion Pipeline Insight” report provides comprehensive global coverage of pipeline therapies for Malignant Pleural Effusion across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitive landscape dynamics, highlighting the strategies of major pharmaceutical companies to advance the pipeline and capitalize on future growth opportunities. In addition, it includes critical insights into clinical trial benchmarking, partnering and licensing activities, and regulatory pathways involving the FDA and EMA, enabling stakeholders to make informed decisions and optimize development strategies within the Malignant Pleural Effusion domain.
Request a sample and discover the recent advances in Malignant Pleural Effusion Drugs @ https://www.delveinsight.com/sample-request/malignant-pleural-effusion-pipeline-insight
Key Takeaways from the Malignant Pleural Effusion Pipeline Report
- In January 2026, Jiangsu Simcere Pharmaceutical Co. Ltd announced Phase III Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions
- DelveInsight’s Malignant Pleural Effusions Pipeline report depicts a robust space with 8+ active players working to develop 8+ pipeline idiopathic pulmonary fibrosis drugs.
- The leading Malignant Pleural Effusions Companies such as LIPAC Oncology, RS Oncology, Clover Biopharmaceuticals, Gongwin Biopharm Holdings, Simcere Pharmaceutical Group and others.
- Promising Malignant Pleural Effusions Therapies such as GL-ONC1-003, RSO-021, CAN-2409, Abnoba Viscum F 20mg, Endostar, zoledronic acid, and others.
Find out more about Malignant Pleural Effusion Drugs @ Malignant Pleural Effusion Treatment
Malignant Pleural Effusion Overview
Malignant pleural effusion is a serious clinical condition characterized by the accumulation of fluid in the pleural space due to the presence of cancer. It commonly occurs in advanced stages of malignancies and is associated with significant morbidity and poor prognosis. MPE most frequently arises from lung cancer, breast cancer, mesothelioma, lymphoma, and ovarian cancer. Cancer cells either directly invade the pleura or disrupt normal lymphatic drainage, leading to excessive fluid buildup. This fluid is typically exudative and often contains malignant cells, which helps confirm the diagnosis.
Malignant Pleural Effusion Emerging Drugs
- LEITP-1009: LIPAC Oncology
LIPAC is developing a new Liposomal Enhanced IntraThoracic Paclitaxel (LEITP) for the treatment of MPM utilizing the LiPax technology. Currently, the drug is being developed in the Pre-Clinical stage of clinical trial evaluation for the treatment of Malignant Pleural Effusion.
- RSO-021: RS Oncology
RSO-021 is a novel irreversible inhibitor of a key mitochondrial enzyme PRX3 (upregulated in cancer cells) regulating oxidative stress pathways. Treatment with RSO-021 will be administered weekly via an intrapleural catheter after routine pleural effusion drainage. RSO-021 therapy has proven to significantly reduce pre-clinically tumor burden in malignant mesothelioma and other cancer types by inhibiting three key enzymes in the antioxidant signaling network within the mitochondria. Covalent adduction of the active site of a key mitochondrial enzyme by RSO-021 inactivates the peroxidase activity of the enzymes leading to accumulation of hydrogen peroxide to levels incompatible with tumor cell survival, while preserving healthy normal cells. RSO-021 is being developed for the treatment of malignant pleural effusion (MPE) via intrapleural (IP) installation in patients suffering from mesothelioma, breast cancer and other indications causing MPE.
- SCB-313: Clover Biopharmaceuticals
SCB-313, has been designed and developed utilizing the Trimer-Tag™ technology platform. SCB-313 is a covalently-linked, native-like trimeric fusion protein which is structurally and functionally differentiated from the dimeric antibody-based structures and other native ligand-based candidates targeting this pathway. SCB-313 has the potential to address the unmet global need for the treatment of intracavitary malignancies, including Malignant Ascites (MA), Malignant Pleural effusions (MPE), and Peritoneal carcinomatosis (PC), as well as additional cancer indications.
The Malignant Pleural Effusion Pipeline Report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Malignant Pleural Effusion with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Malignant Pleural Effusion Treatment.
- Malignant Pleural Effusion Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Malignant Pleural Effusion Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Malignant Pleural Effusion market.
Learn more about Malignant Pleural Effusion Drugs opportunities in our groundbreaking Malignant Pleural Effusion research and development projects @ Malignant Pleural Effusion Unmet Needs
Malignant Pleural Effusion Companies
LIPAC Oncology, RS Oncology, Clover Biopharmaceuticals, Gongwin Biopharm Holdings, Simcere Pharmaceutical Group and others.
Malignant Pleural Effusion pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
Products have been categorized under various Molecule types such as
- Oligonucleotide
- Peptide
- Small molecule
Discover the latest advancements in Malignant Pleural Effusion treatment by visiting our website. Stay informed about how we’re transforming the future of Respiratory Disease @ Malignant Pleural Effusion Market Drivers and Barriers, and Future Perspectives
Scope of the Malignant Pleural Effusion Pipeline Report
- Coverage- Global
- Malignant Pleural Effusion Companies- LIPAC Oncology, RS Oncology, Clover Biopharmaceuticals, Gongwin Biopharm Holdings, Simcere Pharmaceutical Group and others.
- Malignant Pleural Effusions Therapies- GL-ONC1-003, RSO-021, CAN-2409, Abnoba Viscum F 20mg, Endostar, zoledronic acid, and others.
- Malignant Pleural Effusion Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Malignant Pleural Effusion Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Dive deep into rich insights for new Malignant Pleural Effusion Treatments, visit @ Malignant Pleural Effusion Drugs
Table of Contents
- Introduction
- Executive Summary
- Malignant Pleural Effusion : Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Malignant Pleural Effusion – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Mid Stage Products (Phase I/ II)
- RSO-021: RS Oncology
- Early Stage Products (Phase I)
- Preclinical and Discovery Stage Products
- LEITP-1009: LIPAC Oncology
- Inactive Products
- Malignant Pleural Effusion Key Companies
- Malignant Pleural Effusion Key Products
- Malignant Pleural Effusion – Unmet Needs
- Malignant Pleural Effusion – Market Drivers and Barriers
- Malignant Pleural Effusion – Future Perspectives and Conclusion
- Malignant Pleural Effusion Analyst Views
- Malignant Pleural Effusion Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/malignant-pleural-effusion-pipeline-insight